long intergenic non-protein coding RNA 663Genealiases: []
Q-omics provides the consensus-scored LINC00663 profile across patient tissues and cancer cell-line models. LINC00663 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, LINC00663 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, LINC00663 RNA expression shows 21,084 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, THCA, and ACC as cancer lineages where LINC00663 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00663 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00663 survival associations across molecular data types. LINC00663 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00663 RNA expression–survival associations across cancer types. High LINC00663 expression shows unfavorable associations in COAD, but favorable associations in PAAD, LUAD, KIRC, BLCA and MESO. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for LINC00663 RNA expression.
This table summarizes LINC00663 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00663. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00663 shows lower tumor expression in THCA, KICH, UCEC, LUSC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher LINC00663 RNA expression in normal versus tumor tissue (log2 FC = −0.944, t-test p < 0.001).
This table shows molecular features associated with LINC00663 in patient tissues and cancer cell lines. In patient samples, LINC00663 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC00663 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
